Evidence map›Paper›PMID 41929252›Full record

ArticleFrontiers in pharmacology2026

Hericenone C exhibits anti-nociceptive effects through RORα-mediated suppression of TLR4 transcription.

Junhao Li, Kengo Hamamura, Yuya Yoshida, Shimpei Kawano, Shohei Uchinomiya, Jiahongyi Xie, Damiana Scuteri, Yang Ruan, Tomohito Tanihara, Kohei Fukuoka and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Junhao Li *Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Kengo Hamamura *Department of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Yuya YoshidaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Shimpei KawanoDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Shohei UchinomiyaDepartment of Medical Chemistry and Chemical Biology, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Jiahongyi XieDepartment of Agro-Environmental Sciences, Graduate School of Bioresources and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.
Damiana ScuteriDepartment of Health Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy.
Yang RuanJoint International Research Laboratory of Target Discovery and New Drug Innovation, Ministry of Education, School of Traditional Chinese Medicines, China Pharmaceutical University, Nanjing, China.
Tomohito TaniharaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Kohei FukuokaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Orion ZaitsuDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Fumiaki TsurusakiDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Ryotaro TsukamotoDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Takumi NishiDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Taiki FukudaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Tsukasa HamasakiDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Kosuke OyamaDepartment of Biological Science and Technology, Tokyo University of Science, Tokyo, Japan.
Giacinto BagettaPharmacotechnology Documentation and Transfer Unit, Preclinical and Translational Pharmacology, Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, Rende, Italy.
Akio OjidaDepartment of Medical Chemistry and Chemical Biology, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Kuniyoshi ShimizuDepartment of Agro-Environmental Sciences, Graduate School of Bioresources and Bioenvironmental Sciences, Kyushu University, Fukuoka, Japan.
Chaofeng ZhangJoint International Research Laboratory of Target Discovery and New Drug Innovation, Ministry of Education, School of Traditional Chinese Medicines, China Pharmaceutical University, Nanjing, China.
Shigehiro OhdoDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
Naoya MatsunagaDepartment of Clinical Pharmacokinetics, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hericenone C exhibits antinociceptive effects in inflammatory pain; however, its molecular target and underlying mechanism remain unclear. Methods and Results: We assessed the effect of hericenone C on formalin-induced nociceptive behavior in mice and explored its molecular target using Conclusion: Overall, these findings establish hericenone C as a novel RORα antagonist that alleviates inflammatory pain through inhibition of the RORα-TLR4-NF-κB axis in CD11c

Indexed as

CD11cformalin testhericenone CNF-κBnociceptive behaviorp65RORαTLR4

Identifiers

PMID41929252
PMCPMC13038899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.